Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying a type of blood cancer called Acute Myeloid Leukemia (AML), specifically in patients who have a genetic change known as the FLT3 mutation. The study aims to find the best treatment approach for these patients by using a special marker called peripheral blast clearance (PBC) to tailor the therapy. The trial will compare different treatment plans to see which one helps patients live longer without the disease coming back.
The treatments being tested in this study include several medications. One of the main drugs is cytarabine, which is given as an injection. Another medication used is midostaurin, which comes in the form of a soft capsule taken by mouth. Additionally, daunorubicin hydrochloride is used, which is a powder that is mixed and given through an infusion into a vein. Some patients may also receive a placebo, which looks like the real medication but does not contain any active ingredients.
During the study, participants will receive these treatments over a period of time, with the goal of improving their chances of recovery. The study will monitor how well the treatments work and how safe they are for the patients. By using the PBC marker, the study hopes to identify which treatment plan is most effective for patients with the FLT3 mutation in AML. The results of this study could help doctors better understand how to treat this type of leukemia in the future.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
8 criteria
7 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a type of medication used in this trial to target a specific mutation found in some acute myeloid leukemia (AML) patients. This medication works by blocking the activity of the FLT3 protein, which is often overactive in these patients. By inhibiting this protein, the medication aims to slow down or stop the growth of cancer cells, helping to improve the patient's condition.
is a treatment approach used in the trial to aggressively target and kill cancer cells. This therapy involves using higher doses of chemotherapy drugs than usual to increase the chances of eliminating cancer cells from the body. The goal is to reduce the number of cancer cells significantly, which can help in achieving remission in patients with AML.
is a procedure included in the trial as part of the consolidation phase of treatment. This therapy involves replacing the patient's diseased bone marrow with healthy bone marrow from a donor. The new bone marrow can produce healthy blood cells, which can help restore the patient's immune system and improve their chances of recovery from AML.
This treatment involves the administration of chemotherapy medications at doses higher than standard, given intravenously (through a vein). It is used as early intensification in the treatment of acute myeloid leukemia with a FLT3 mutation, especially in patients who show low sensitivity to conventional chemotherapy, as assessed by the clearance of diseased cells (blasts) from the peripheral blood. Its mechanism of action is based on destroying cancer cells with chemical substances that interfere with these cells' ability to multiply and grow. This approach belongs to the class of intensified chemotherapy treatments and is considered an important component in fighting this aggressive form of leukemia.
This procedure consists of replacing the patient's blood-producing cells with healthy cells from a compatible donor, administered intravenously after the diseased cells have been eliminated through intensive chemotherapy. It is used as consolidation treatment in patients with acute myeloid leukemia who have a FLT3 mutation and a poor initial response to treatment, with the aim of preventing relapse of the disease. The mechanism works through the complete replacement of the diseased blood-production system with a healthy one, allowing the new cells to recognize and eliminate any remaining cancer cells. This treatment represents one of the most effective forms of curative therapy for high-risk leukemias.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.